ABL
Nicolas Salavin is the Chief Technology Officer and Biomanufacturing Site Head at ABL Europe, previously holding roles such as Senior Director at Sanofi Pasteur, Head of Department at TOTAL, and Bioprocess Industrialization Manager at sanofi-aventis. With a Masters in Biotechnology and Process Engineering from AgroParisTech, Nicolas has a strong background in project management, industrial biotech projects, downstream processing, and fermentation science. Nicolas has experience in driving change, performance, and transformation programs within global manufacturing technologies networks.
This person is not in any teams
This person is not in any offices
ABL
From development to market ABL Europe provides GMP viral vectors, contributing to the success of our clients’ immunotherapy innovations. ABL Europe SAS is a pure-play GMP CMO licensed in accordance with EMA, completely dedicated to the provision of viral vector GMP contract manufacturing services, and a subsidiary of ABL Inc. under the corporate ownership of Institut Mérieux. ABL has a strong technical & regulatory track record in process development, scale-up & GMP manufacturing of filterable & non-sterile filterable (aseptic processing) viral vectors used in all phases of clinical development globally. With different adherent platforms (< 60 m2) and suspension (< 500 L) capabilities for drug substance and drug product (< 10,000 vials per batch) in-house, experience in process characterisation and validation, ABL provides its clients with a long-term strategic manufacturing option through clinical development & licensure for a range of virus vector gene therapy & vaccine products. ABL Europe’s clients are located worldwide.